| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
797.75(M) |
| Last
Volume: |
4,409,980 |
Avg
Vol: |
4,464,222 |
| 52
Week Range: |
$4.5 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Abercrombie George B |
Director |
• • – |
2021-09-15 |
4 |
AS |
$15.06 |
$75,300 |
D/D |
(5,000) |
0 |
|
-1% |
|
| Abercrombie George B |
Director |
• • – |
2021-09-15 |
4 |
OE |
$2.63 |
$13,150 |
D/D |
5,000 |
5,000 |
|
- |
|
| Lee Kenneth B Jr |
Director |
• • – |
2021-09-13 |
4 |
S |
$15.35 |
$92,100 |
D/D |
(6,000) |
24,252 |
|
8% |
|
| Lee Kenneth B Jr |
Director |
• • – |
2021-09-13 |
4 |
OE |
$3.22 |
$48,300 |
D/D |
15,000 |
30,252 |
|
- |
|
| Abercrombie George B |
Director |
• • – |
2021-09-10 |
4 |
S |
$15.09 |
$1,116,660 |
D/D |
(74,000) |
0 |
|
9% |
|
| Abercrombie George B |
Director |
• • – |
2021-09-10 |
4 |
OE |
$1.71 |
$202,710 |
D/D |
71,000 |
74,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2021-09-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
10,000 |
5,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2021-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
778,602 |
|
- |
|
| Levin Alan G |
Director |
• • – |
2021-08-31 |
4 |
A |
$15.92 |
$9,998 |
D/D |
628 |
628 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2021-08-31 |
4 |
A |
$15.92 |
$18,738 |
D/D |
1,177 |
77,378 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2021-08-31 |
4 |
A |
$15.92 |
$4,999 |
D/D |
314 |
32,444 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2021-08-31 |
4 |
A |
$15.92 |
$9,998 |
D/D |
628 |
14,794 |
|
- |
|
| Abercrombie George B |
Director |
• • – |
2021-07-15 |
4 |
AS |
$15.69 |
$78,450 |
D/D |
(5,000) |
3,000 |
|
-25% |
|
| Abercrombie George B |
Director |
• • – |
2021-07-15 |
4 |
OE |
$2.63 |
$13,150 |
D/D |
5,000 |
8,000 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2021-06-10 |
4 |
AS |
$16.86 |
$393,394 |
D/D |
(23,333) |
65,073 |
|
-13% |
|
| Hutson Nancy J |
Director |
• • – |
2021-06-10 |
4 |
OE |
$2.85 |
$73,549 |
D/D |
23,333 |
88,406 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2021-05-28 |
4 |
A |
$15.77 |
$18,735 |
D/D |
1,188 |
76,201 |
|
- |
|
| Aselage Steve |
Director |
• • – |
2021-05-28 |
4 |
A |
$15.77 |
$9,998 |
D/D |
634 |
32,130 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2021-05-28 |
4 |
A |
$15.77 |
$4,999 |
D/D |
317 |
65,073 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2021-05-28 |
4 |
A |
$15.77 |
$4,999 |
D/D |
317 |
14,166 |
|
- |
|
| Sheridan William P |
Chief Medical Officer |
• • – |
2021-05-28 |
4 |
AS |
$15.02 |
$1,379,046 |
D/D |
(91,814) |
14,475 |
|
-14% |
|
| Sheridan William P |
Chief Medical Officer |
• • – |
2021-05-28 |
4 |
OE |
$4.73 |
$493,826 |
D/D |
91,814 |
106,289 |
|
- |
|
| Sheridan William P |
Chief Medical Officer |
• • – |
2021-05-27 |
4 |
AS |
$15.00 |
$1,076,385 |
D/D |
(71,759) |
14,475 |
|
-7% |
|
| Sheridan William P |
Chief Medical Officer |
• • – |
2021-05-27 |
4 |
OE |
$4.73 |
$378,114 |
D/D |
71,759 |
86,234 |
|
- |
|
| Abercrombie George B |
Director |
• • – |
2021-05-24 |
4 |
AS |
$13.90 |
$92,671 |
D/D |
(6,667) |
3,000 |
|
3% |
|
77 Records found
|
|
Page 1 of 4 |
|
|
0.17 (3.88%) 
